Month: February 2021

AB “Novaturas” invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on the February 10, 2021 at 9.30 am (EET). The presentation will be held in English.The webinar will be hosted by the Chief Executive Officer of the Company Audronė Keinytė and CFO Tomas Staškūnas who will introduce the Company’s unaudited financial results for the year 2020 and will answer the participants’ questions.After the presentation investors are welcome to ask questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until February 9th at Emilija.Ivanauskaite@nasdaq.comHow to join the webinar?To join the webinar, please register via following link: https://attendee.gotowebinar.com/register/2559180796620089360. You will be provided with the webinar...

AB “Novaturas” kviečia akcininkus, investuotojus, analitikus ir visus besidominčius į 2020 metų finansinių rezultatų pristatymą internetiniame seminare (angl. „webinar“).Pradžia – 2021 m. vasario 10 d. 9.30 val. Seminaras vyks anglų kalba.Bendrovės generalinė direktorė Audronė Keinytė ir finansų direktorius Tomas Staškūnas pakomentuos bendrovės finansinius veiklos rezultatus ir po pristatymo atsakys į dalyvių klausimus.Dėl riboto seminarui skirto laiko, maloniai prašome atsiųsti klausimus iš anksto iki 2021 m. vasario 9 d. el. paštu: Emilija.Ivanauskaite@nasdaq.com.Kaip prisijungti prie internetinio seminaro?Visus norinčius dalyvauti internetiniame seminare, prašome registruotis aktyvuojant šią nuorodą: https://attendee.gotowebinar.com/register/2559180796620089360. Jums bus išsiųsta nuoroda prisijungti į internetinį seminarą ir instrukcija,...

In Just Over a Week “Willy’s Wonderland” Trailer Has Generated Over 15 Million Impressions for Chicken Soup for the Soul Entertainment’s Screen Media VenturesNEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) — Screen Media Ventures, a Chicken Soup for the Soul Entertainment, Inc. (Nasdaq: CSSE) company, announced today the trailer for the upcoming February 12, 2021 PVOD (premium video-on-demand) release of horror thriller Willy’s Wonderland, starring Nicolas Cage with Emily Tosta, Ric Reitz, Chris Warner, and Beth Grant, has generated over 15 million impressions across YouTube and social media platforms, the most in the history of the company.The Landmark Studio Group feature is directed by Kevin Lewis from a screenplay written by G.O. Parsons. In Willy’s Wonderland, a quiet loner (Cage) finds himself stranded in a remote town when his car...

San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced that members of its leadership team will present at several upcoming investment events in February, including the Small-Cap Growth Investor Conference, the Money Show February Virtual Expo, and the Benzinga Cannabis Capital Conference taking place virtually.Small Cap Growth Investor ConferencePunit Dhillon, CEO of Skye Bioscience, will present a company overview at the Small Cap Growth Investor Conference on February 4, 2021. Details of the presentation are as follows:Presentation Date: Thursday, February 4, 2021Presentation Time:  3:30 PM...

NORWALK, Conn., Feb. 03, 2021 (GLOBE NEWSWIRE) — Reed’s Inc. (NASDAQ: REED), America’s #1 ginger company, today announces a distribution partnership with Unique Foods Inc. to expand the company’s retail footprint throughout Canada.The new master agreement between Reed’s Inc. and Unique Foods, Canada’s leading distributor for healthy beverages, will establish a larger presence for the company’s world-famous Reed’s Ginger Beer and Virgil’s, their line of handcrafted, all-natural sodas. The strategic partnerships will provide increased availability for Reed’s Ginger Beer in both Extra and Original varieties, and Virgil’s handcrafted sodas, in Root Beer, Vanilla Cream, Black Cherry and Orange Cream flavors, across all channels of business in Canada.“We are thrilled to launch this new partnership with Unique Foods, and we look forward...

MIAMI, Feb. 03, 2021 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, February 18, 2021. OPKO’s senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on February 18th beginning at 4:30 p.m. Eastern time.CONFERENCE CALL & WEBCAST INFORMATIONOPKO encourages participants to pre-register for the conference call using the link here or dialing (888) 869-1189 or (706) 643-5902 and using conference ID 8597848. Upon registering, participants will receive dial-in numbers, an event passcode and a unique registrant ID to gain immediate access to the call and bypass...

TORONTO, Feb. 03, 2021 (GLOBE NEWSWIRE) — Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that the Company has entered into a consulting agreement with the biomedical industry veteran Gregg Mayer, Founder & Principal of BioCore Strategies, LLC, Boston, Massachusetts, USA, and former executive of Abbott Diagnostics, Siemens and a number of early-stage biopharma and medical device companies, both public and privately held. Mr. Mayer will lead TELO’s efforts to develop and execute the Company’s industry partnership strategy with Biopharma and Diagnostics industries.“I have previously collaborated with Gregg and am thrilled to have him onboard leading Telo Genomics efforts to develop the Company’s industry partnership strategy,” said Guido Baechler, TELO Chairman. “Gregg brings 35 years of executive...

NEW YORK, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,899,827 entitled “Antibodies Specific for Sulfation Sites of Sclerostin”.The new patent is a member of a broader U.S. and international patent family that also includes issued patents and pending patent applications for therapies including monoclonal antibodies and small synthetic peptides used to inhibit sclerostin in the treatment of bone disorders such as osteoporosis. Enzo’s patent focuses on polyclonal antibodies that bind a specific region of human sclerostin, a protein that is a negative regulator of bone growth. Sclerostin is produced in osteocytes, a type of bone cell, and is known to inhibit bone formation. The maintenance...